Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Investors in Novavax, Inc. (Symbol: NVAX) saw new options begin trading today, for the July 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVAX ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Short interest in Novavax Inc (NASDAQ:NVAX) increased during the last reporting period, rising from 42.33M to 46.47M. This put 28.79% of the company's publicly available shares short. Short ...

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate ...

This was the stock's second consecutive day of losses.

Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the ...

The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable limitations. Previously available under emergency use authorization for ...

Novavax (NVAX) stock in focus as the U.S. FDA approves its COVID-19 vaccine Nuvaxovid for high-risk groups in the U.S. Read more here.

Shares of Novavax Inc. NVAX shed 1.52% to $7.15 Wednesday, on what proved to be an all-around mixed trading session for the ...